Skip to main content
SpringerLink
Log in

Intense pulsed light for meibomian gland dysfunction: a systematic review and meta-analysis

Graefe's Archive for Clinical and Experimental Ophthalmology volume 259, pages 1–10 (2021)Cite this article

Abstract

Background

Intense pulsed light therapy (IPL) is a new method being used to treat meibomian gland dysfunction (MGD) globally. With an increasing number of studies being published, it is necessary to consider additional factors related to treatment. This review aims to investigate the efficacy and safety of IPL for the treatment of MGD.

Methods

The PubMed, EMBASE, Web of Science, Cochrane Library, Google Scholar, China National Knowledge Infrastructure (CNKI), Wanfang, VIP, and SinoMed databases were searched through February 24, 2020. Randomized clinical trials and cohort studies comparing IPL+ meibomian gland expression (MGX) or IPL alone with control groups were included. The weighted mean difference (WMD) was calculated to analyze the Ocular Surface Disease Index (OSDI) score and Standard Patient Evaluation of Eye Dryness (SPEED) score, and the standard mean difference (SMD) was calculated to analyze the tear breakup time (TBUT). Heterogeneity was quantified by the I2 statistic ranging from 0 to 100%, and a random effects model was used in this meta-analysis. All analyses were performed by RevMan 5.3. All p values were calculated by the t test, and p values were regarded as statistically significant at p < 0.05. The Cochrane Collaboration’s tool for assessing risk of bias was used to identify and evaluate bias in the literature.

Results

Nine studies with a total of 539 patients were included. Eight studies examined TBUT, six examined OSDI scores, and four examined SPEED scores. IPL combined with MGX showed superiority regarding the TBUT (SMD 2.33, 95% CI 1.04–3.61), and OSDI scores (WMD 11.93, 95% CI − 17.10 to − 6.77), with high heterogeneity. The SPEED scores were not significantly different.

Conclusions

IPL combined with MGX may be an effective and safe treatment for MGD, but it cannot improve all symptoms. IPL alone is not superior to MGX. The efficacy is also affected by the number and average frequency of treatments. The efficacy of IPL may decrease within 6 months after the last treatment, so it should be considered a long-term adjuvant therapy combined with MGX. When patients receive 3 or 4 treatments (once every 3–4 weeks), a return visit at 6 months after the last treatment is required.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

References

  1. Stapleton F, Alves M, Bunya VY et al (2017) TFOS DEWS II Epidemiology Report. Ocul Surf 15(3):334–365

    Article  PubMed  Google Scholar 

  2. Farrand KF, Fridman M, Stillman IÖ, Schaumberg DA (2017) Prevalence of diagnosed dry eye disease in the United States among adults aged 18 years and older. Am J Ophthalmol 182:90–98

    Article  PubMed  Google Scholar 

  3. Schaumberg DA, Sullivan DA, Buring JE, Dana MR (2003) Prevalence of dry eye syndrome among US women. Am J Ophthalmol 136(2):318–326

    Article  PubMed  Google Scholar 

  4. Yun CM, Kang SY, Kim HM, Song JS (2012) Prevalence of dry eye disease among university students. J Korean Ophthalmol Soc 53(4):505–509

  5. Korb DR, Greiner JV, Herman JP et al (2002)Lid-wiper epitheliopathy and dry-eye symptoms in contact lens wearers. CLAO J 28(4):211–216

    PubMed  Google Scholar 

  6. Ozcura F, Aydin S, Helvaci MR (2007) Ocular surface disease index for the diagnosis of dry eye syndrome. Ocul Immunol Inflamm 15:389–393

    Article  PubMed  Google Scholar 

  7. Akpek EK, Amescua G, Farid M et al (2019) Dry eye syndrome preferred practice pattern. Ophthalmology 126(1):286–334

    Article  Google Scholar 

  8. Pflugfelder SC, Solomon A, Stern ME (2000) The diagnosis and management of dry eye: a twenty-five-year review. Cornea 19:644–649

    Article  CAS  PubMed  Google Scholar 

  9. Craig JP, Nichols KK, Akpek EK et al (2017) TFOS DEWS II Definition and classification report. Ocul Surf 15(3):276–283

    Article  PubMed  Google Scholar 

  10. Rabensteiner DF, Aminfar H, Boldin I et al (2018) The prevalence of meibomian gland dysfunction, tear film and ocular surface parameters in an Austrian dry eye clinic population. Acta Ophthalmol 96:E707–E711

    Article  PubMed  PubMed Central  Google Scholar 

  11. Lemp MA, Crews LA, Bron AJ et al (2012) Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea 31(5):472–478

    Article  PubMed  Google Scholar 

  12. Viso E, Gude F, Rodríguez-Ares MT (2011) The association of meibomian gland dysfunction and other common ocular diseases with dry eye: a population-based study in Spain. Cornea 30(1):1–6

    Article  PubMed  Google Scholar 

  13. Tong L, Chaurasia SS, Mehta JS et al (2010) Screening for meibomian gland disease: its relation to dry eye subtypes and symptoms in a tertiary referral clinic in Singapore. Invest Ophthalmol Vis Sci 51:3449–3454

    Article  PubMed  Google Scholar 

  14. Baudouin C, Messmer EM, Aragona P et al (2016) Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol 100(3):300–306

    Article  PubMed  Google Scholar 

  15. Tomlinson A, Bron AJ, Korb DR et al (2011) The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Invest Ophthalmol Vis Sci 52:2006–2049

    Article  PubMed  PubMed Central  Google Scholar 

  16. Liu ZG, Sun XG, Zhang MC et al (2017) Expert consensus on diagnosis and treatment of meibomian gland dysfunction in China. Chin J Ophthalmol 53(9):657–661

    Google Scholar 

  17. Buckley RJ (2018) Assessment and management of dry eye disease. Eye 32(2):200–203

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Toyos R, McGill W, Briscoe D (2015) Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study. Photomed Laser Surg 33(1):41–46

    Article  PubMed  PubMed Central  Google Scholar 

  19. Toyos R, McGill W, Briscoe D (2015) Intense pulse light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study. Photomed Laser Surg 33:41–46

    Article  PubMed  PubMed Central  Google Scholar 

  20. Craig JP, Chen YH, Turnbull PR (2015) Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 56(3):1965–1970

    Article  PubMed  Google Scholar 

  21. Vegunta S, Patel D, Shen JF (2016) Combination therapy of intense pulsed light therapy and meibomian gland expression (IPL/MGX) can improve dry eye symptoms and meibomian gland function in patients with refractory dry eye: a retrospective analysis. Cornea 35(3):318–322

    Article  PubMed  Google Scholar 

  22. Gupta PK, Vora GK, Matossian C et al (2016) Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease. Can J Ophthalmol 51(4):249–253

    Article  PubMed  Google Scholar 

  23. Jiang X, Lv H, Song H et al (2016) Evaluation of the safety and effectiveness of intense pulsed light in the treatment of meibomian gland dysfunction. J Ophthalmol 2016:1910694

    PubMed  PubMed Central  Google Scholar 

  24. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA statement. PLoS Med 6(6):e1000097

    Article  PubMed  PubMed Central  Google Scholar 

  25. Reiko A, Shima F, Naoyuki M (2019) Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocul Surf 17(1):104–110

    Article  Google Scholar 

  26. Li Y (2017) Clinical study of meibomian gland massage combined intense pulsed light in dry eye caused by meibomian gland dysfunction. Dissertation, Shandong University

  27. Bin L (2019) Effect of intense pulsed light combined with meibomian gland massage on tear film rupture time in patients with dry eye of dysfunctional meibomian gland. Shiyongfangmangjishu 4:159–161

    Google Scholar 

  28. Yonrawee P, Ngamjit K, Usanee R et al (2020) Efficacy and safety of intense pulsed light in patients with meibomian gland dysfunction-a randomized, double-masked, sham-controlled clinical trial. Cornea 39(3):325–332

    Article  Google Scholar 

  29. Rong B, Tang Y, Ping T et al (2018) Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomed Laser Surg 36(6):326–332

    Article  PubMed  Google Scholar 

  30. Rong B, Tang Y, Ping T et al (2018) Long-term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomed Laser Surg 36(10):562–567

    Article  CAS  PubMed  Google Scholar 

  31. Xue Ally L, Wang Michael TM, Ormonde Susan E et al (2020) Randomised double-masked placebo-controlled trial of the cumulative treatment efficacy profile of intense pulsed light therapy for meibomian gland dysfunction. The Ocular Surface 18(2):286–297

    Article  CAS  PubMed  Google Scholar 

  32. Yue Y, Ninghua L, Lan G et al (2017) Changes in the meibomian gland after exposure to intense pulsed light in meibomian gland dysfunction (MGD) patients. Curr Eye Res 43(3):308–313

    Google Scholar 

  33. Zhang BD, Shi W, Zhang G et al (2018) Clinical study of intense pulsed light in treating meibomian gland dysfunction dry eye. J Shanxi Med  47(09):1048–1050

  34. Sambhi RDS, Sambhi GDS, Mather R et al (2020) Intense pulsed light therapy with meibomian gland expression for dry eye disease. Can J Ophthalmol 55(3):189–198

    Article  PubMed  Google Scholar 

  35. Dell Steven J (2017) Intense pulsed light for evaporative dry eye disease. Clin Ophthalmol 11:1167

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Yang L, Chen D, Chen X et al (2019) Hypoxia: a breath of fresh air for the meibomian gland. Ocul Surf 17(2):310–317

    Article  Google Scholar 

Download references

Funding

This study was supported by The Special Planning Task of Sichuan Youth Scientific and Technological Innovation Research Team (No. 2017td0030).

Author information

Authors and Affiliations

  1. Chengdu University of Traditional Chinese Medicine, Sichuan Province, Chengdu, 610000, China

    Leng Xiangjie, Shi Meirong, Liu Xinyu, Cui Jingzhe & Lu Xuejing

  2. Department of Ophthalmology, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu Province, 210000, China

    Sun Huaping

  3. Department of Ophthalmology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province, 210000, China

    Sun Huaping

  4. Department of Ophthalmology, Eye College of Chengdu University of TCM, Sichuan Province, Chengdu, 610000, China

    Lu Xuejing

  5. Department of Ophthalmology, Ineye Hospital of Chengdu University of TCM, Sichuan Province, Chengdu, 610000, China

    Lu Xuejing

  6. Department of Ophthalmology, Key Laboratory of Sichuan Province Ophthalmopathy Prevention & Cure and Visual Function Protection with TCM, Sichuan Province, Chengdu, 610000, China

    Lu Xuejing

Authors
  1. Leng Xiangjie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shi Meirong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liu Xinyu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Cui Jingzhe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sun Huaping
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lu Xuejing
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Xiangjie Leng and Xuejing Lu had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Xiangjie Leng, Meirong Shi, and Xinyu Liu.

Acquisition, analysis, or interpretation of data: Xiangjie Leng, Meirong Shi, and Jingzhe Cui.

Drafting of the manuscript: Xiangjie Leng, Meirong Shi, Xinyu Liu, and Jingzhe Cui.

Critical revision of the manuscript for important intellectual content: Xuejing Lu and Huaping Sun.

Statistical analysis: Xiangjie Leng and Meirong Shi.

Administrative, technical, or material support: Xuejing Lu.

Supervision: Xuejing Lu and Huaping Sun.

Corresponding author

Correspondence to Lu Xuejing.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(PDF 441 kb)

ESM 2

(PDF 23 kb)

ESM 3

(PDF 47 kb)

ESM 4

(PDF 239 kb)

ESM 5

(PDF 303 kb)

ESM 6

(PNG 103 kb)

ESM 7

(PDF 513 kb)

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Leng, X., Shi, M., Liu, X. et al. Intense pulsed light for meibomian gland dysfunction: a systematic review and meta-analysis. Graefes Arch Clin Exp Ophthalmol 259, 1–10 (2021). https://doi.org/10.1007/s00417-020-04834-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00417-020-04834-1

Keywords

search

Navigation